SS
ESPR

Sunbelt Securities’s Esperion Therapeutics ESPR Stock Holding History

Sunbelt Securities’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7
Closed -$26 – 3000
2025
Q4 		$26 Buy
+7
New +$23 ﹤0.01% 2709
2025
Q3 		– Sell
-100
Closed -$220 – 2741
2025
Q2 		$220 Hold
100
– – ﹤0.01% 1744
2025
Q1 		$144 Hold
100
– – ﹤0.01% 1751
2024
Q4 		$215 Hold
100
– – ﹤0.01% 1750
2024
Q3 		$165 Hold
100
– – ﹤0.01% 1798
2024
Q2 		$222 Hold
100
– – ﹤0.01% 1699
2024
Q1 		$268 Hold
100
– – ﹤0.01% 1655
2023
Q4 		$299 Hold
100
– – ﹤0.01% 1614
2023
Q3 		$98 Hold
100
– – ﹤0.01% 1727
2023
Q2 		$139 Hold
100
– – ﹤0.01% 1641
2023
Q1 		$167 Buy
+100
New +$516 ﹤0.01% 1599

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sunbelt Securities's ESPR Position: Q1 2026 in Review

Sunbelt Securities sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 7 shares — an estimated $26 sold.

Sunbelt Securities first reported a position in ESPR in Q1 2023 and held it in 11 quarters. The position peaked at $299 in Q4 2023. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Sunbelt Securities reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sunbelt Securities sold 7 Esperion Therapeutics shares in Q1 2026, an estimated $26.
  • Sunbelt Securities first reported a position in Esperion Therapeutics in Q1 2023 and held it in 11 quarters.
  • Sunbelt Securities's Esperion Therapeutics position peaked at $299 in Q4 2023.
  • 207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.